Silverfin false false 31/03/2026 01/04/2025 31/03/2026 L Ferrara 15/08/2024 A Janeczek 01/09/2022 R Oreffo 22/03/2017 J A Otter 22/03/2017 22 July 2026 no description of principal activity 10685524 2026-03-31 10685524 bus:Director1 2026-03-31 10685524 bus:Director2 2026-03-31 10685524 bus:Director3 2026-03-31 10685524 bus:Director4 2026-03-31 10685524 2025-03-31 10685524 core:CurrentFinancialInstruments 2026-03-31 10685524 core:CurrentFinancialInstruments 2025-03-31 10685524 core:ShareCapital 2026-03-31 10685524 core:ShareCapital 2025-03-31 10685524 core:SharePremium 2026-03-31 10685524 core:SharePremium 2025-03-31 10685524 core:RetainedEarningsAccumulatedLosses 2026-03-31 10685524 core:RetainedEarningsAccumulatedLosses 2025-03-31 10685524 core:PatentsTrademarksLicencesConcessionsSimilar 2025-03-31 10685524 core:PatentsTrademarksLicencesConcessionsSimilar 2026-03-31 10685524 core:OfficeEquipment 2025-03-31 10685524 core:ComputerEquipment 2025-03-31 10685524 core:OtherPropertyPlantEquipment 2025-03-31 10685524 core:OfficeEquipment 2026-03-31 10685524 core:ComputerEquipment 2026-03-31 10685524 core:OtherPropertyPlantEquipment 2026-03-31 10685524 bus:OrdinaryShareClass1 2026-03-31 10685524 2025-04-01 2026-03-31 10685524 bus:FilletedAccounts 2025-04-01 2026-03-31 10685524 bus:SmallEntities 2025-04-01 2026-03-31 10685524 bus:AuditExemptWithAccountantsReport 2025-04-01 2026-03-31 10685524 bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 10685524 bus:Director1 2025-04-01 2026-03-31 10685524 bus:Director2 2025-04-01 2026-03-31 10685524 bus:Director3 2025-04-01 2026-03-31 10685524 bus:Director4 2025-04-01 2026-03-31 10685524 core:PatentsTrademarksLicencesConcessionsSimilar core:TopRangeValue 2025-04-01 2026-03-31 10685524 core:OfficeEquipment core:TopRangeValue 2025-04-01 2026-03-31 10685524 core:ComputerEquipment core:TopRangeValue 2025-04-01 2026-03-31 10685524 core:OtherPropertyPlantEquipment core:TopRangeValue 2025-04-01 2026-03-31 10685524 2024-04-01 2025-03-31 10685524 core:PatentsTrademarksLicencesConcessionsSimilar 2025-04-01 2026-03-31 10685524 core:OfficeEquipment 2025-04-01 2026-03-31 10685524 core:ComputerEquipment 2025-04-01 2026-03-31 10685524 core:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 10685524 bus:OrdinaryShareClass1 2025-04-01 2026-03-31 10685524 bus:OrdinaryShareClass1 2024-04-01 2025-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 10685524 (England and Wales)

RENOVOS BIOLOGICS LIMITED

Unaudited Financial Statements
For the financial year ended 31 March 2026
Pages for filing with the registrar

RENOVOS BIOLOGICS LIMITED

Unaudited Financial Statements

For the financial year ended 31 March 2026

Contents

RENOVOS BIOLOGICS LIMITED

BALANCE SHEET

As at 31 March 2026
RENOVOS BIOLOGICS LIMITED

BALANCE SHEET (continued)

As at 31 March 2026
Note 2026 2025
£ £
Fixed assets
Intangible assets 3 4,251 5,668
Tangible assets 4 36,446 47,934
40,697 53,602
Current assets
Debtors 5 50,890 147,234
Cash at bank and in hand 6 168,464 152,119
219,354 299,353
Creditors: amounts falling due within one year 7 ( 45,090) ( 50,074)
Net current assets 174,264 249,279
Total assets less current liabilities 214,961 302,881
Net assets 214,961 302,881
Capital and reserves
Called-up share capital 8 37 37
Share premium account 1,492,918 1,492,918
Profit and loss account ( 1,277,994 ) ( 1,190,074 )
Total shareholders' funds 214,961 302,881

For the financial year ending 31 March 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of Renovos Biologics Limited (registered number: 10685524) were approved and authorised for issue by the Board of Directors. They were signed on its behalf by:

J A Otter
Director

22 July 2026

RENOVOS BIOLOGICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
RENOVOS BIOLOGICS LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2026
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Renovos Biologics Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 2 Venture Road Southampton Science Park, Chilworth, Southampton, SO16 7NP, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Employee benefits

Defined contribution schemes
The Company operates a defined contribution scheme. The amount charged to the Profit and Loss Account in respect of pension costs and other post-retirement benefits is the contributions payable in the financial year. Differences between contributions payable in the financial year and contributions actually paid are included as either accruals or prepayments in the Balance Sheet.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Trademarks, patents and licences 10 years straight line
Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Office equipment 5 years straight line
Computer equipment 5 years straight line
Other property, plant and equipment 5 years straight line

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

The Company as lessee
Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Government grants

Government grants are recognised based on the accrual model and are measured at the fair value of the asset received or receivable. Grants are classified as relating either to revenue or to assets. Grants relating to revenue are recognised in income over the period in which the related costs are recognised. Grants relating to assets are recognised over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income.

2. Employees

2026 2025
Number Number
Monthly average number of persons employed by the Company during the year, including directors 6 7

3. Intangible assets

Trademarks, patents
and licences
Total
£ £
Cost
At 01 April 2025 14,170 14,170
At 31 March 2026 14,170 14,170
Accumulated amortisation
At 01 April 2025 8,502 8,502
Charge for the financial year 1,417 1,417
At 31 March 2026 9,919 9,919
Net book value
At 31 March 2026 4,251 4,251
At 31 March 2025 5,668 5,668

4. Tangible assets

Office equipment Computer equipment Other property, plant
and equipment
Total
£ £ £ £
Cost
At 01 April 2025 1,208 2,786 107,882 111,876
At 31 March 2026 1,208 2,786 107,882 111,876
Accumulated depreciation
At 01 April 2025 99 1,303 62,540 63,942
Charge for the financial year 241 402 10,845 11,488
At 31 March 2026 340 1,705 73,385 75,430
Net book value
At 31 March 2026 868 1,081 34,497 36,446
At 31 March 2025 1,109 1,483 45,342 47,934

5. Debtors

2026 2025
£ £
Prepayments 2,535 2,534
VAT recoverable 547 4,202
Corporation tax 47,808 140,498
50,890 147,234

6. Cash and cash equivalents

2026 2025
£ £
Cash at bank and in hand 168,464 152,119

7. Creditors: amounts falling due within one year

2026 2025
£ £
Trade creditors 9 940
Accruals 37,870 46,305
Other taxation and social security 4,572 0
Other creditors 2,639 2,829
45,090 50,074

8. Called-up share capital

2026 2025
£ £
Allotted, called-up and fully-paid
368,072 Ordinary shares of £ 0.0001 each 37 37

9. Financial commitments

Commitments

2026 2025
£ £
Total future minimum lease payments under non-cancellable operating leases 8,442 1,809

Pensions

The Company operates a defined contribution pension scheme for the directors and employees. The assets of the scheme are held separately from those of the Company in an independently administered fund.

The Company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Company in an independently fund. The pension cost charge represents contributions payable by the Company to the fund and amounted to £16,047 (2025: £11,017). Contributions totalling £2,636 (2025: £2,829) were payable to the fund at the balance sheet date and are included in other creditors.